Mapol
Mapol Inc. is a Canadian market access consulting firm that helps innovative pharmaceutical manufacturers navigate private and public payer drug plans via payer strategy, data analytics (DRM Reports, Claims Analytics, Time-to-Listing forecasts), and stakeholder engagement, supported by a 450+-member MAES subscription and Canada's leading accredited payer webinar series.
- Company typePrivate
- Founded2012
- HeadquartersMississauga, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Mapol does
Mapol Inc. is a Canadian market access consulting firm founded in 2012 and headquartered in Mississauga, Ontario. The company serves innovative pharmaceutical manufacturers seeking to navigate Canada's private and public payer drug plans, from regulatory approval through formulary listing and reimbursement adoption. Its offerings are organized around three pillars: Payer Strategy (landscape assessments, payer advisory boards with former decision-makers, and hands-on market access support), Data Services (Drug Reimbursement Monitor [DRM] Reports described as an industry-standard benchmark, plus custom Claims Analytics and Time-to-Listing forecasts), and Payer Engagement (submission support, Canada's leading accredited payer webinar series with over 100 sessions, and direct stakeholder meetings). The supporting technology platform aggregates more than 2,000,000 proprietary data points on drug coverage across Canadian plans.
The company monetizes through two primary streams: (1) a subscription membership called Market Access Essential Services (MAES), which provides payer profiles, submission guides, stakeholder maps, time-to-listing reports, a weekly Rapid Intelligence Monitor, and the monthly Drug Benefit Communiqué® — relied on by 450+ members across Canada's pharmaceutical industry; and (2) project-based market access consulting engagements billed as professional services. Pricing is not publicly disclosed; subscriptions and consulting are quote-based. The firm operates a direct enterprise sales motion via website contact, phone, and email outreach to pharmaceutical manufacturers, positioning itself as an extension of the client's market access team. It also runs a French-language site variant and complies with PIPEDA, Quebec Law 25, WCAG 2.1 AA, and AODA accessibility standards.
Mapol is a privately held, founder-owned company with a small team (1-10 employees) led by co-founder Johnny Ma (President & COO), a pharmacist with 25+ years of experience including prior tenure as a private payer decision-maker. The leadership bench includes directors overseeing operations, data services, client services, and finance/marketing. The firm operates exclusively in the Canadian market and has supported patient access for hundreds of drugs since inception. No external funding rounds, institutional investors, or M&A activity are disclosed in the available data.
Mapol firmographics
Firmographics- Name
- Mapol
- Legal name
- Mapol Inc.
- Website
- https://www.mapol.ca
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Mapol Inc. is a Canadian market access consulting firm that helps innovative pharmaceutical manufacturers navigate private and public payer drug plans via payer strategy, data analytics (DRM Reports, Claims Analytics, Time-to-Listing forecasts), and stakeholder engagement, supported by a 450+-member MAES subscription and Canada's leading accredited payer webinar series.
- Ownership category
- akta.pro rank
Mapol industry classification
Industry- Product category
- Pharmaceutical Market Access Consulting
- akta.pro primary industry
- Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH)
Keywords
Where Mapol is headquartered
LocationHeadquarters
- HQ city
- Mississauga
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Mapol business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- MAES Subscription (Market Access Essential Services): Subscription-based membership providing payer profiles, tools, and insights including Rapid Intelligence Monitor (weekly), Drug Benefit Communiqué (monthly), payer profiles, submission guides, stakeholder maps, and time-to-listing reports. Over 450 members subscribe to this service.
- Market Access Consulting Services: Custom consulting engagements covering payer strategy (landscape assessments, payer advisory boards, market access support), data services, and payer engagement (submissions, webinar series, stakeholder meetings). Billed as professional services engagements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Mapol product offering
Product offeringCore offering
Mapol is a market access solutions provider that helps innovative pharmaceutical manufacturers navigate Canada's private and public payer drug plans. It combines three core service areas—Payer Strategy (landscape assessments, payer advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports and Claims Analytics), and Payer Engagement (submissions, accredited webinar series, stakeholder meetings)—alongside the Market Access Essential Services (MAES) subscription membership.
Product overview
Mapol is a market access solutions provider offering an integrated platform combining three core service areas: Payer Strategy (landscape assessments, advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports, Claims Analytics), and Payer Engagement (submissions, Payer Webinar Series, stakeholder meetings). These services are delivered alongside a subscription membership called Market Access Essential Services (MAES), which provides payer profiles, submission guides, stakeholder maps, time-to-listing forecasts, the Rapid Intelligence Monitor weekly briefing, and Drug Benefit Communique monthly bulletin. The company focuses exclusively on helping innovative pharmaceutical manufacturers navigate Canada's private and public drug plans since 2012.
Differentiator
Problem solved
Functional benefit
Brands
- Drug Reimbursement Monitor (DRM): Industry standard reports for drug coverage intelligence measuring quality of coverage and lives facing reimbursement barriers across private and public plans.
- Drug Benefit Communiqué®
- Rapid Intelligence Monitor
- Market Access Essential Services (MAES)
Products and services
- Payer Strategy Strategic consulting services helping innovative pharmaceutical manufacturers anticipate payer responses through landscape assessments, payer advisory boards with former decision-makers, and hands-on market access support from submission through listing and beyond.
- Data Services Data analytics offerings centered on Drug Reimbursement Monitor (DRM) Reports providing industry-standard coverage intelligence and claims analytics revealing how plan design shapes real-world utilization patterns across private and public payer plans.
- Payer Engagement Services connecting pharmaceutical manufacturers with private and public payers through submissions to insurers and PLA consortiums, Canada's leading accredited payer webinar series, and direct one-on-one stakeholder meetings with drug plan managers, benefits advisors, and decision-makers.
- Market Access Essential Services (MAES) A comprehensive subscription membership providing payer profiles, submission guides, stakeholder maps, time-to-listing forecasts, rapid intelligence monitoring, and the Drug Benefit Communiqué monthly bulletin, relied on by 450+ members across Canada's pharmaceutical companies.
- Drug Reimbursement Monitor (DRM) Reports The industry-standard benchmark for drug coverage intelligence measuring coverage quality and lives facing reimbursement barriers across private and public plans, with snapshot analysis, uptake tracking, and pre-launch forecasting.
- Claims Analytics Custom analyses revealing how plan design (managed formularies, prior authorization, tiering) shapes real-world claims patterns over time, down to regional and sales-territory level.
- Payer Webinar Series Canada's leading continuing-education webinar series with over 100 C.E.-accredited sessions connecting pharmaceutical manufacturers with the private payer community of insurers, benefits advisors, PBMs, TPAs, and employers.
- Rapid Intelligence Monitor A weekly summary of changes to private and public payer market access policies, included in the MAES membership.
- Drug Benefit Communiqué A registered monthly digest with timely analysis of policy changes impacting private and public payer plans, included in the MAES membership.
- Time-to-Listing Reports Forecasts of uptake in private payer plans based on historical time-to-listing benchmarks, included in the MAES membership.
Quantifiable outcome
- Supported patient access for hundreds of drugs from submission to formulary listing
- +2 more outcomes
Companies that use Mapol
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Mapol technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Mapol partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights2 records
Mapol competitors and assessment
Company assessmentDirect peers
- PDCI Market Access: Canadian market access and reimbursement consulting firm serving pharmaceutical manufacturers with pricing, reimbursement, and health economics services — the closest direct peer to Mapol in Canada.
Broad incumbents
- IQVIA: Global life sciences data and consulting powerhouse offering market access, HEOR, RWE, and commercial services across all major geographies; competes with Mapol for manufacturer market access budgets at the high end.
- ZS Associates: Global management consulting and analytics firm with a deep pharmaceutical practice covering market access, launch excellence, and sales/marketing — competes for the same manufacturer clients with broader capabilities.
- Trinity Life Sciences: Life sciences commercial consulting firm offering market access, evidence, and brand strategy services — overlaps with Mapol's payer strategy and engagement offerings for innovative pharma manufacturers.
- Evidera (PPD / Thermo Fisher): Health economics, outcomes research, and market access consultancy providing payer evidence and reimbursement strategy — competes for similar manufacturer budgets on the evidence and strategy side.
- Syneos Health: Global biopharmaceutical services organization with consulting and commercialization capabilities, including market access and payer engagement — competes for innovative manufacturer engagements.
Regional players
- Innomar Strategies (Cencora): Canadian pharma services firm (now part of Cencora) offering patient support, market access, and distribution services — directly comparable Canadian-focused competitor with broader patient services reach.
Emerging players
- BresMed: Health economics and market access consultancy serving pharma and medical device clients across multiple geographies — overlapping but more specialized in HEOR than Mapol's payer-focused practice.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
Mapol social profiles
Digital presenceMapol compliance and trust
Trust signalCompliance2 records
Mapol financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mapol leadership team
Management profileNumber of profiles
Profiles9 records
Mapol funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mapol M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mapol
What does Mapol do?
Mapol is a market access solutions provider that helps innovative pharmaceutical manufacturers navigate Canada's private and public payer drug plans. It combines three core service areas—Payer Strategy (landscape assessments, payer advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports and Claims Analytics), and Payer Engagement (submissions, accredited webinar series, stakeholder meetings)—alongside the Market Access Essential Services (MAES) subscription membership.
Is Mapol a public or private company?
Mapol is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Mapol founded?
Mapol was founded in 2012. It employs 1 to 10 people.
Where is Mapol based?
Mapol is headquartered in Mississauga, Canada, in the North America region.
How does Mapol make money?
Two revenue lines are on record. MAES Subscription (Market Access Essential Services) is the primary driver. The others are market Access Consulting Services.
Who are Mapol's main competitors?
PDCI Market Access is listed as a direct peer. Broad incumbents are IQVIA, ZS Associates, Trinity Life Sciences, Evidera (PPD / Thermo Fisher) and Syneos Health. Innomar Strategies (Cencora) is listed as a regional player. BresMed is listed as an emerging player.
Does Mapol have an API?
No public API is recorded for Mapol.
What industry is Mapol in?
Mapol's product category is Pharmaceutical Market Access Consulting. Its primary akta.pro industry code is HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools.